Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

Yan Wang, Yongcheng Huang, Helen H. Hobbs, Jonathan C. Cohen

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that promotes degradation of cell surface LDL receptors (LDLRs) in selected cell types. Here we used genetic and pharmacological inhibitors to define the pathways involved in PCSK9-mediated LDLR degradation. Inactivating mutations in autosomal recessive hypercholesterolemia (ARH), an endocytic adaptor, blocked PCSK9-mediated LDLR degradation in lymphocytes but not in fibroblasts. Thus, ARH is not specifically required for PCSK9-mediated LDLR degradation. Knockdown of clathrin heavy chain with siRNAs prevented LDLR degradation. In contrast, prevention of ubiquitination of the LDLR cytoplasmic tail, inhibition of proteasomal activity, or disruption of proteins required for lysosomal targeting via macroautophagy (autophagy related 5 and 7) or the endosomal sorting complex required for trafficking (ESCRT) pathway (hepatocyte growth factor-regulated Tyr-kinase substrate and tumor suppressor gene 101) failed to block PCSK9-mediated LDLR degradation. These findings are consistent with a model in which the LDLR-PCSK9 complex is internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination and is distinct from the autophagy and proteosomal degradation pathways. Finally, the PCSK9-LDLR complex appears not to be transported by the canonical ESCRT pathway.

Original languageEnglish (US)
Pages (from-to)1932-1943
Number of pages12
JournalJournal of Lipid Research
Volume53
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Proprotein Convertases
Subtilisin
LDL Receptors
Degradation
Autophagy
Ubiquitination
Sorting
Clathrin Heavy Chains
Proprotein Convertase 9
Clathrin
Hepatocyte Growth Factor
Lymphocytes
Cell Surface Receptors
Fibroblasts
Endocytosis
Lysosomes
Tumor Suppressor Genes
Proteolysis
Tumors
Proteins

Keywords

  • Autophagy
  • Cholesterol
  • Endosomes
  • Low density lipoprotein receptor
  • Lysosomes

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Endocrinology

Cite this

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. / Wang, Yan; Huang, Yongcheng; Hobbs, Helen H.; Cohen, Jonathan C.

In: Journal of Lipid Research, Vol. 53, No. 9, 09.2012, p. 1932-1943.

Research output: Contribution to journalArticle

@article{3bcb4468b7ac4e219f55623df75486d6,
title = "Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR",
abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that promotes degradation of cell surface LDL receptors (LDLRs) in selected cell types. Here we used genetic and pharmacological inhibitors to define the pathways involved in PCSK9-mediated LDLR degradation. Inactivating mutations in autosomal recessive hypercholesterolemia (ARH), an endocytic adaptor, blocked PCSK9-mediated LDLR degradation in lymphocytes but not in fibroblasts. Thus, ARH is not specifically required for PCSK9-mediated LDLR degradation. Knockdown of clathrin heavy chain with siRNAs prevented LDLR degradation. In contrast, prevention of ubiquitination of the LDLR cytoplasmic tail, inhibition of proteasomal activity, or disruption of proteins required for lysosomal targeting via macroautophagy (autophagy related 5 and 7) or the endosomal sorting complex required for trafficking (ESCRT) pathway (hepatocyte growth factor-regulated Tyr-kinase substrate and tumor suppressor gene 101) failed to block PCSK9-mediated LDLR degradation. These findings are consistent with a model in which the LDLR-PCSK9 complex is internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination and is distinct from the autophagy and proteosomal degradation pathways. Finally, the PCSK9-LDLR complex appears not to be transported by the canonical ESCRT pathway.",
keywords = "Autophagy, Cholesterol, Endosomes, Low density lipoprotein receptor, Lysosomes",
author = "Yan Wang and Yongcheng Huang and Hobbs, {Helen H.} and Cohen, {Jonathan C.}",
year = "2012",
month = "9",
doi = "10.1194/jlr.M028563",
language = "English (US)",
volume = "53",
pages = "1932--1943",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "9",

}

TY - JOUR

T1 - Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

AU - Wang, Yan

AU - Huang, Yongcheng

AU - Hobbs, Helen H.

AU - Cohen, Jonathan C.

PY - 2012/9

Y1 - 2012/9

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that promotes degradation of cell surface LDL receptors (LDLRs) in selected cell types. Here we used genetic and pharmacological inhibitors to define the pathways involved in PCSK9-mediated LDLR degradation. Inactivating mutations in autosomal recessive hypercholesterolemia (ARH), an endocytic adaptor, blocked PCSK9-mediated LDLR degradation in lymphocytes but not in fibroblasts. Thus, ARH is not specifically required for PCSK9-mediated LDLR degradation. Knockdown of clathrin heavy chain with siRNAs prevented LDLR degradation. In contrast, prevention of ubiquitination of the LDLR cytoplasmic tail, inhibition of proteasomal activity, or disruption of proteins required for lysosomal targeting via macroautophagy (autophagy related 5 and 7) or the endosomal sorting complex required for trafficking (ESCRT) pathway (hepatocyte growth factor-regulated Tyr-kinase substrate and tumor suppressor gene 101) failed to block PCSK9-mediated LDLR degradation. These findings are consistent with a model in which the LDLR-PCSK9 complex is internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination and is distinct from the autophagy and proteosomal degradation pathways. Finally, the PCSK9-LDLR complex appears not to be transported by the canonical ESCRT pathway.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that promotes degradation of cell surface LDL receptors (LDLRs) in selected cell types. Here we used genetic and pharmacological inhibitors to define the pathways involved in PCSK9-mediated LDLR degradation. Inactivating mutations in autosomal recessive hypercholesterolemia (ARH), an endocytic adaptor, blocked PCSK9-mediated LDLR degradation in lymphocytes but not in fibroblasts. Thus, ARH is not specifically required for PCSK9-mediated LDLR degradation. Knockdown of clathrin heavy chain with siRNAs prevented LDLR degradation. In contrast, prevention of ubiquitination of the LDLR cytoplasmic tail, inhibition of proteasomal activity, or disruption of proteins required for lysosomal targeting via macroautophagy (autophagy related 5 and 7) or the endosomal sorting complex required for trafficking (ESCRT) pathway (hepatocyte growth factor-regulated Tyr-kinase substrate and tumor suppressor gene 101) failed to block PCSK9-mediated LDLR degradation. These findings are consistent with a model in which the LDLR-PCSK9 complex is internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination and is distinct from the autophagy and proteosomal degradation pathways. Finally, the PCSK9-LDLR complex appears not to be transported by the canonical ESCRT pathway.

KW - Autophagy

KW - Cholesterol

KW - Endosomes

KW - Low density lipoprotein receptor

KW - Lysosomes

UR - http://www.scopus.com/inward/record.url?scp=84864851760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864851760&partnerID=8YFLogxK

U2 - 10.1194/jlr.M028563

DO - 10.1194/jlr.M028563

M3 - Article

VL - 53

SP - 1932

EP - 1943

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 9

ER -